Ms Cyntia Genolet is IFPMA’s Policy Analyst, Regulatory & Health Policy and leads the organisation’s anti-counterfeiting portfolio. In this short interview, she gives a brief summary about the threat posed by counterfeit medicines and factors encouraging the trade of counterfeit medicines. In 2015, IFPMA is organising two workshops on counterfeit medicines in Asia and Africa.
Read moreFor all the advances it has produced, globalisation also has its downsides. One such example, the counterfeiting of medical products, represents a major threat to our societies, in particular the poorest ones. The data is rare and difficult to verify with certainty. According to the World Health Organisation (WHO), about 15% of medicines in the...
Read moreMs Cyntia Genolet, IFPMA’s Policy Analyst, Regulatory & Health Policy and leads the organisation’s anti-counterfeiting portfolio, together with Marc Gentilini, General Delegate of ‘Fondation Chirac’ give their take on what fake medicines are and how to curb their threat.
Read moreIn a globalized world, the regulatory landscape is changing every day to address, in tandem, old and new challenges. With regulatory systems increasingly under pressure globally, what will be the most promising weapons in the fight to make regulatory systems in Africa work more efficiently? And how to pay the bill for the extensive regulatory...
Read moreThis IFPMA video illustrates what biotherapeutics are all about. They are typically derived from living organisms and are made by genetically engineering DNA. A high level of precision is required in the commercial manufacturing process to produce a consistent product each time. Every step we take in the production of these medicines requires highly controlled...
Read moreProviding new therapies to patients living with unmet needs faster and more efficiently is an industry-wide challenge. A major key to improving the speed cost and quality of drug development is harnessing the insights of the customer – patients themselves. The traditional model of clinical development has looked at drug development through the lens of...
Read moreA new study entitled The Economic Footprint of the Pharmaceutical Industry – Regional breakdown and differentiation between originators and generics, independently conducted by WifOR reveals how the pharmaceutical industry, one of the world’s largest industries, plays a major role in boosting the global economy across regions. The study was commissioned by the IFPMA and aims...
Read moreThe aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond...
Read more